E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Public ClinicalTrials.gov record NCT05686226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.
Study identification
- NCT ID
- NCT05686226
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Cervical Cancer
- Throat Cancer
- Oropharynx Cancer
- Anal Cancer
- Vulva Cancer
- Vaginal Cancer
- Penile Cancer
- Metastatic Cancer
- HPV-Related Malignancy
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Adenocarcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- HPV-Associated Vaginal Adenocarcinoma
- HPV-Related Adenosquamous Carcinoma
- HPV-Related Endocervical Adenocarcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV Positive Rectal Squamous Cell Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2023
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Jun 11, 2026
2023 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08901 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05686226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05686226 live on ClinicalTrials.gov.